The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUnilever Regulatory News (ULVR)

Share Price Information for Unilever (ULVR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,113.00
Bid: 4,112.00
Ask: 4,113.00
Change: 31.00 (0.76%)
Spread: 1.00 (0.024%)
Open: 4,100.00
High: 4,146.00
Low: 4,098.00
Prev. Close: 4,082.00
ULVR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Unilever to sell its Tea business ekaterra

18 Nov 2021 16:20

RNS Number : 8808S
Unilever PLC
18 November 2021
 

Unilever to sell its Tea business, ekaterra, to CVC Capital Partners Fund VIII for €4.5 bn

 

 

London, 18 November 2021 - Unilever today announced that it has entered into an agreement to sell its global Tea business, ekaterra, to CVC Capital Partners Fund VIII for €4.5 billion on a cash-free, debt-free basis.

 

ekaterra is the world's leading Tea business, with a portfolio of 34 brands including Lipton, PG tips, Pukka, T2 and TAZO®. The business generated revenues of around €2 billion in 2020.

 

Alan Jope, CEO of Unilever said: "The evolution of our portfolio into higher growth spaces is an important part of our growth strategy for Unilever. Our decision to sell ekaterra demonstrates further progress in delivering against our plans.

 

"We are proud of the place that our Tea business has in our company's history. We look forward to seeing ekaterra, with its strong brands and global footprint, prosper under CVC's ownership. I would like to thank our Tea colleagues around the world for their passion and commitment to our Tea business and wish them well for the future."

 

Pev Hooper, a Managing Partner at CVC Capital Partners said: "ekaterra is a great business, built on strong foundations of leading brands and a purpose-driven approach to its products, people and communities. ekaterra is well positioned in an attractive market to accelerate its future growth, and to lead the category's sustainable development. We look forward to working with the team to realise ekaterra's full potential."

 

John Davison, CEO of ekaterra, said: "ekaterra is a strong business with positive momentum and has an exciting future ahead under the new ownership of CVC. We look forward to the next stage of our journey as the world's leading Tea business."

 

Completion of the transaction is subject to completion of works council consultation processes and the receipt of certain regulatory approvals. Completion is expected in the second half of 2022. The transaction perimeter excludes Unilever's Tea business in India, Nepal and Indonesia as well as Unilever's interests in the Pepsi Lipton ready-to-drink Tea joint ventures and associated distribution businesses.

 

 

About ekaterra

ekaterra is the leading global Tea business, with world class purpose driven brands including Lipton, PG tips, Pukka, T2 and TAZO®. With 11 production factories in 4 continents and Tea estates in 3 countries, ekaterra is growing a world of wellbeing through the regenerative power of plants. https://ekaterratea.com/

 

 

About CVC Capital Partners

CVC is a leading private equity and investment advisory firm with a network of 25 offices throughout Europe, Asia and the US, with approximately US$125 billion of assets under management. Since its founding in 1981, CVC has secured commitments in excess of US$165 billion from some of the world's leading institutional investors across its private equity and credit strategies. Funds managed or advised by CVC are invested in more than 100 companies worldwide, which have combined annual sales of over US$100 billion and employ more than 450,000 people. For further information about CVC please visit: http://cvc.com 

 

 

Unilever PLC

Unilever House100 Victoria EmbankmentLondon EC4Y 0DYUnited Kingdom

 

Press-Office.London@Unilever.com

 

 

 

Jonathan Sibun

+44 777 999 9683

jsibun@tulchangroup.com 

 

Guy Bates

+44 781 293 5831

gbates@tulchangroup.com

 

Ellen van Ginkel

+31 623915635

ellen-van.ginkel@unilever.com 

 

 

 

Safe Harbour

 

This announcement may contain forward-looking statements, including 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995. Words such as 'will', 'aim', 'expects', 'anticipates', 'intends', 'looks', 'believes', 'vision', or the negative of these terms and other similar expressions of future performance or results, and their negatives, are intended to identify such forward-looking statements. These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Unilever Group (the 'Group'). They are not historical facts, nor are they guarantees of future performance.

 

Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially are: Unilever's global brands not meeting consumer preferences; Unilever's ability to innovate and remain competitive; Unilever's investment choices in its portfolio management; the effect of climate change on Unilever's business; Unilever's ability to find sustainable solutions to its plastic packaging; significant changes or deterioration in customer relationships; the recruitment and retention of talented employees; disruptions in our supply chain and distribution; increases or volatility in the cost of raw materials and commodities; the production of safe and high quality products; secure and reliable IT infrastructure; execution of acquisitions, divestitures and business transformation projects; economic, social and political risks and natural disasters; financial risks; failure to meet high and ethical standards; and managing regulatory, tax and legal matters. A number of these risks have increased as a result of the current Covid-19 pandemic. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, the Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

Further details of potential risks and uncertainties affecting the Group are described in the Group's filings with the London Stock Exchange, Euronext Amsterdam and the US Securities and Exchange Commission, including in the Annual Report on Form 20-F 2020 and the Unilever Annual Report and Accounts 2020 available on our corporate website.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFLRLILTLIL
Date   Source Headline
25th Apr 20247:00 amRNSQ1 2024 Trading Statement
2nd Apr 20243:58 pmRNSTotal Voting Rights
28th Mar 20245:04 pmRNSDirector/PDMR Shareholding
27th Mar 202412:32 pmRNSDirector/PDMR Shareholding
26th Mar 20246:13 pmRNSDirector/PDMR Shareholding
26th Mar 202411:58 amRNSDirector/PDMR Shareholding
25th Mar 20243:10 pmRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSUnilever to accelerate Growth Action Plan
18th Mar 20243:00 pmRNSNotice of AGM
14th Mar 20242:14 pmRNSAnnual Financial Report
13th Mar 20247:00 amRNSBlock Listing of Shares
11th Mar 20245:55 pmRNSDirector/PDMR Shareholding
1st Mar 20242:36 pmRNSTotal Voting Rights
19th Feb 20243:14 pmRNSDirector/PDMR Shareholding
8th Feb 20247:00 amRNSFinal Results
1st Feb 20245:04 pmRNSTotal Voting Rights
31st Jan 20243:00 pmRNSDirectorate Change
16th Jan 20245:10 pmRNSBlock listing Interim Review
2nd Jan 20242:54 pmRNSTotal Voting Rights
27th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20235:48 pmRNSDirector/PDMR Shareholding
12th Dec 20235:51 pmRNSDirector/PDMR Shareholding
11th Dec 20235:48 pmRNSDirector/PDMR Shareholding
11th Dec 20235:43 pmRNSDirector/PDMR Shareholding
4th Dec 20235:28 pmRNSTotal Voting Rights
23rd Nov 20233:51 pmRNSDirector/PDMR Shareholding
22nd Nov 20235:44 pmRNSDirector/PDMR Shareholding
10th Nov 20235:33 pmRNSDirector/PDMR Shareholding
8th Nov 20236:05 pmRNSDirector/PDMR Shareholding
1st Nov 20233:36 pmRNSTotal Voting Rights
30th Oct 20234:33 pmRNSStatement re Director Remuneration Report AGM Vote
26th Oct 20237:01 amRNSUnilever Announces New CFO
26th Oct 20237:00 amRNS3rd Quarter Results
18th Oct 20232:00 pmRNSCompletion of the 4th Tranche Share Buyback
17th Oct 20235:57 pmRNSTransaction in Own Shares
16th Oct 20236:01 pmRNSTransaction in Own Shares
13th Oct 20235:58 pmRNSTransaction in Own Shares
12th Oct 20235:50 pmRNSTransaction in Own Shares
12th Oct 20239:04 amRNSChanges to Membership of Board Committees
11th Oct 20236:06 pmRNSTransaction in Own Shares
11th Oct 20234:37 pmRNSDirector/PDMR Shareholding
10th Oct 20235:42 pmRNSTransaction in Own Shares
9th Oct 20236:05 pmRNSTransaction in Own Shares
6th Oct 20235:55 pmRNSTransaction in Own Shares
5th Oct 20235:46 pmRNSTransaction in Own Shares
4th Oct 20235:54 pmRNSTransaction in Own Shares
3rd Oct 20235:40 pmRNSTransaction in Own Shares
2nd Oct 20236:10 pmRNSTransaction in Own Shares
2nd Oct 20233:57 pmRNSTotal Voting Rights
28th Sep 20236:02 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.